泰德医药(03880.HK)公布招股结果，香港公开发售接获301.15倍认购，一手(100股)中签率50%，认购2万股获稳派一手。按回补机制，公开发售股份已增至840万股，占发售总数50%。国际发售录得2.43倍认购。最终发售价30.6元，上限定价，集资净额4.29亿元。股份预期周一(30日)上市。
合约研究，开发及生产机构(CRDMO)泰德医药是次拟全球发售1,680万股，公开发售原占10%。招股价介乎28.4-30.6元。基石投资者石药(01093.HK) 及腾讯(00700.HK) 前高管吴宵光创立的微光创投分别认购500万美元股份。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-06-27 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.